COMPUGEN - unentdeckter Bioinformatikwert - 500 Beiträge pro Seite
eröffnet am 24.11.01 18:07:29 von
neuester Beitrag 20.03.02 18:37:53 von
neuester Beitrag 20.03.02 18:37:53 von
Beiträge: 4
ID: 511.386
ID: 511.386
Aufrufe heute: 0
Gesamt: 831
Gesamt: 831
Aktive User: 0
ISIN: IL0010852080 · WKN: 553001 · Symbol: CW9
1,7800
EUR
-0,45 %
-0,0080 EUR
Letzter Kurs 22.04.24 Tradegate
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,0000 | +67,36 | |
| 1,4800 | +33,82 | |
| 5,8400 | +25,78 | |
| 0,7600 | +22,58 | |
| 2,9200 | +18,70 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6825 | -17,76 | |
| 6,5500 | -18,13 | |
| 3,3500 | -18,89 | |
| 0,6021 | -35,26 | |
| 3,9400 | -43,31 |
Feedback
Obwohl die Compugen-Aktie immer wieder hervorragende Nachrichten hervorbringt, wird sie in Deutschland so gut wie nie gehandelt. An der NASDAQ hingegen werden täglich um die 200.000 Stück umgesetzt. Wie kommt`s?
Anbei ein aktueller Artikel zum Unternehmen:
Sigma-Genosys and Compugen Introduce Genome Libraries For High Throughput Analysis of Gene Function
San Diego, CA - October 25, 2001
Sigma-Genosys, a member of the Sigma-Aldrich family (NASDAQ: SIAL), and Compugen (NASDAQ:CGEN) announced today the commercial launch of OligoLibrariesTM, co-branded genome oligonucleotide collections for gene expression profiling, at the 13th International Genome Sequencing and Analysis Conference (GSAC) in San Diego.
In June 2001, the two companies announced an alliance for the design, manufacture and commercialization of three designated OligoLibraries representing the mouse, rat and human genome. Compugen leverages its LEADSTM platform and DNA Chip Design Services to address redundancy, incorporate alternative splicing and consider specificity and cross-homology while developing content and designs for the genome collections. Sigma-Genosys manufactures the products using its patented AbacusTM oligo synthesis platform and technologies. The products are co-marketed by both parties under a revenue sharing agreement. Customers of the OligoLibraries will be able to access certain gene sequences and other information relating to OligoLibraries through Compugen`s LabOnWeb (www.labonweb.com) life science Internet research engine.
These genome libraries have been available under a limited early access program within Johns Hopkins University, the Medical Research Council, UK, the National Institutes of Health, National University of Singapore, National Cancer Institute`s Advanced Technology Center at Gaithersburg, Maryland and University of North Carolina.
The public launch of OligoLibraries now provides the life sciences research community with access to oligonucleotide collections for high throughput gene expression analysis, drug discovery and functional assays.
"These new oligonucleotide collections, utilizing Sigma-Genosys` expertise in long oligo production and Compugen`s superior computational biology, provide the researcher with a more accurate and informative look at the human, mouse and rat genomes," said David Julien, President of the Biotechnology division of Sigma-Aldrich.
"Our collaboration with a market leader such as Sigma-Aldrich allows us to deliver the highest understanding of the human, mouse and rat genomes for the analysis of gene function. Together we are able to offer a high-quality manufacturing process combined with data precision and design accuracy, creating the best product currently available," said Mor Amitai, Ph.D., President and Chief Executive Officer of Compugen. "We are encouraged by the early market enthusiasm and have received positive feedback from initial results obtained by several early access customers," he added.
About Sigma-Aldrich
Sigma-Aldrich (NASDAQ:SIAL) is a leading Life Science and High Technology company. The Company`s biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and chemical manufacturing with customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 33 countries and has over 6,000 employees providing excellent service worldwide. Sigma-Genosys, Inc., based in Houston, Texas, is a global leader in custom synthetic DNA. Sigma-Aldrich is committed to the success of its customers, employees and shareholders through Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award winning Web site at www.sigma-aldrich.com.
About Compugen
Compugen (Nasdaq: CGEN) develops and markets platforms, tools and products that accelerate post-genomic research, the advanced study of proteins and protein pathways, and drug target discovery. Compugen`s in-house molecular biology laboratories conduct original genomic and proteomic research and also provide validation for Compugen`s methodologies. Products commercialized to date include: LEADS, Gencarta, DNA Chip design, Z3, ProtoCall, LabOnWeb.com and Bioccelerators. For additional information, please visit Compugen`s Corporate Web Site at www.cgen.com and the Company`s Internet research engine for molecular biologists, www.LabOnWeb.com.
This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding Sigma-Aldrich`s and Compugen`s expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the companies` operations and investments and conditions in the markets they serve. These statements include words like "may," "expects," "believes," and "intends," or similar expressions and describe opinions about future events. Although the companies believe the expectations are based on reasonable assumptions, these forward-looking statements are subject to risks and uncertainties that may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; the ability to implement technological improvements; the ability of the companies to obtain and retain customers. These and other factors are identified and more fully explained in management`s discussion and analysis in Sigma-Aldrich`s most recent Form 10-Q filed with the Securities and Exchange Commission and under the heading "Risk Factors" in Compugen`s Registration Statement on Form F-1 filed with the Securities and Exchange Commission. The companies do not undertake any obligation to update these forward-looking statements.
Anbei ein aktueller Artikel zum Unternehmen:
Sigma-Genosys and Compugen Introduce Genome Libraries For High Throughput Analysis of Gene Function
San Diego, CA - October 25, 2001
Sigma-Genosys, a member of the Sigma-Aldrich family (NASDAQ: SIAL), and Compugen (NASDAQ:CGEN) announced today the commercial launch of OligoLibrariesTM, co-branded genome oligonucleotide collections for gene expression profiling, at the 13th International Genome Sequencing and Analysis Conference (GSAC) in San Diego.
In June 2001, the two companies announced an alliance for the design, manufacture and commercialization of three designated OligoLibraries representing the mouse, rat and human genome. Compugen leverages its LEADSTM platform and DNA Chip Design Services to address redundancy, incorporate alternative splicing and consider specificity and cross-homology while developing content and designs for the genome collections. Sigma-Genosys manufactures the products using its patented AbacusTM oligo synthesis platform and technologies. The products are co-marketed by both parties under a revenue sharing agreement. Customers of the OligoLibraries will be able to access certain gene sequences and other information relating to OligoLibraries through Compugen`s LabOnWeb (www.labonweb.com) life science Internet research engine.
These genome libraries have been available under a limited early access program within Johns Hopkins University, the Medical Research Council, UK, the National Institutes of Health, National University of Singapore, National Cancer Institute`s Advanced Technology Center at Gaithersburg, Maryland and University of North Carolina.
The public launch of OligoLibraries now provides the life sciences research community with access to oligonucleotide collections for high throughput gene expression analysis, drug discovery and functional assays.
"These new oligonucleotide collections, utilizing Sigma-Genosys` expertise in long oligo production and Compugen`s superior computational biology, provide the researcher with a more accurate and informative look at the human, mouse and rat genomes," said David Julien, President of the Biotechnology division of Sigma-Aldrich.
"Our collaboration with a market leader such as Sigma-Aldrich allows us to deliver the highest understanding of the human, mouse and rat genomes for the analysis of gene function. Together we are able to offer a high-quality manufacturing process combined with data precision and design accuracy, creating the best product currently available," said Mor Amitai, Ph.D., President and Chief Executive Officer of Compugen. "We are encouraged by the early market enthusiasm and have received positive feedback from initial results obtained by several early access customers," he added.
About Sigma-Aldrich
Sigma-Aldrich (NASDAQ:SIAL) is a leading Life Science and High Technology company. The Company`s biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and chemical manufacturing with customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 33 countries and has over 6,000 employees providing excellent service worldwide. Sigma-Genosys, Inc., based in Houston, Texas, is a global leader in custom synthetic DNA. Sigma-Aldrich is committed to the success of its customers, employees and shareholders through Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award winning Web site at www.sigma-aldrich.com.
About Compugen
Compugen (Nasdaq: CGEN) develops and markets platforms, tools and products that accelerate post-genomic research, the advanced study of proteins and protein pathways, and drug target discovery. Compugen`s in-house molecular biology laboratories conduct original genomic and proteomic research and also provide validation for Compugen`s methodologies. Products commercialized to date include: LEADS, Gencarta, DNA Chip design, Z3, ProtoCall, LabOnWeb.com and Bioccelerators. For additional information, please visit Compugen`s Corporate Web Site at www.cgen.com and the Company`s Internet research engine for molecular biologists, www.LabOnWeb.com.
This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding Sigma-Aldrich`s and Compugen`s expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the companies` operations and investments and conditions in the markets they serve. These statements include words like "may," "expects," "believes," and "intends," or similar expressions and describe opinions about future events. Although the companies believe the expectations are based on reasonable assumptions, these forward-looking statements are subject to risks and uncertainties that may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; the ability to implement technological improvements; the ability of the companies to obtain and retain customers. These and other factors are identified and more fully explained in management`s discussion and analysis in Sigma-Aldrich`s most recent Form 10-Q filed with the Securities and Exchange Commission and under the heading "Risk Factors" in Compugen`s Registration Statement on Form F-1 filed with the Securities and Exchange Commission. The companies do not undertake any obligation to update these forward-looking statements.
KURSEXPLOSION BEI COMPUGEN (553001)!!!
Es scheint endlich loszugehen!
Es scheint endlich loszugehen!
Wednesday March 20, 4:17 am Eastern Time
Compugen, Millennium In Software R&D Project
JERUSALEM -(Dow Jones)- Israel `s Compugen Ltd. (CGEN) said Wednesday that it will collaborate with U.S. -based Millennium Pharmaceuticals (NasdaqNM: MLNM - news) Inc. (MLNM) to develop software tools to assist in predicting protein pathways for use in drug discovery and development.
The two companies will share the costs of the project and the rights to certain aspects of the technology developed.
This is Millennium`s first collaboration with an Israeli biotechnology company.
Yigal Koltin, vice president of international R&D alliance development at Millennium, said his company will continue to seek additional opportunities for partnerships within the Israeli biotechnology industry.
Compugen, Millennium In Software R&D Project
JERUSALEM -(Dow Jones)- Israel `s Compugen Ltd. (CGEN) said Wednesday that it will collaborate with U.S. -based Millennium Pharmaceuticals (NasdaqNM: MLNM - news) Inc. (MLNM) to develop software tools to assist in predicting protein pathways for use in drug discovery and development.
The two companies will share the costs of the project and the rights to certain aspects of the technology developed.
This is Millennium`s first collaboration with an Israeli biotechnology company.
Yigal Koltin, vice president of international R&D alliance development at Millennium, said his company will continue to seek additional opportunities for partnerships within the Israeli biotechnology industry.
heutige Präsentation auf Bio Konferenz. CGEN auf 4,33$ gestiegen +5%
March 19-21, 2002
Tel Aviv, Israel
Booth #63
Come hear Dr. Hagai Karchi, Compugen Ltd.
"Enabling Technologies and Tools for the Development of Bioproducts"
Wednesday, March 20, 9:00 AM - 1:00 PM
Come hear Dr. Mor Amitai, CEO and President
"Computer Aided Drugs Discovery and Bioinformatics"
Wednesday, March 20, 2:30-6:00 PM
http://www.kenes.com/biotech/wel.htm
March 19-21, 2002
Tel Aviv, Israel
Booth #63
Come hear Dr. Hagai Karchi, Compugen Ltd.
"Enabling Technologies and Tools for the Development of Bioproducts"
Wednesday, March 20, 9:00 AM - 1:00 PM
Come hear Dr. Mor Amitai, CEO and President
"Computer Aided Drugs Discovery and Bioinformatics"
Wednesday, March 20, 2:30-6:00 PM
http://www.kenes.com/biotech/wel.htm
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +1,04 | |
| -0,07 | |
| +0,41 | |
| +1,27 | |
| +3,06 | |
| +1,32 | |
| -10,73 | |
| +1,89 | |
| +100,00 | |
| +0,27 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 189 | ||
| 126 | ||
| 86 | ||
| 73 | ||
| 57 | ||
| 48 | ||
| 40 | ||
| 30 | ||
| 30 | ||
| 27 |
